【研究生系列报告】（191）The Resurgence of Covalent Drug（2017年9月1日）
The Resurgence of Covalent Drug
Reporter: Xuedong Li
CAS Key laboratory of Molecular Recognition and Function, Institute of Chemistry, CAS
Small molecule drugs exert their pharmacological effects through binding to biomolecular targets, thereby modulating their activity (in the enzymes) or downstream signaling (in the case of receptors) with biological consequences that are relevant to the disease state being treated. In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biological target. The prevalence and pharmacological advantage of covalent drugs will be briefly covered, followed by an introduction to their mechanism of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.
 J. Singh et al., Nat. Rev. Drug Discov., 2011, 11, 307-317.
 N. Moitessier et al. Eur. J. Med. Chem., 2017, 138, 96-114.
 A. S. Kalgutkar et al. Expert. Opin. Drug Discov., 2012, 7, 561-581.
 Y. Aye et al. Cell Chem. Bio., 2017, 24, 787-800.
2010-2014 HeBei North University
2014-present Institute of Chemistry, CAS Ph.D. (Supervisor. Prof. Liang Cheng)